UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January, 2024.
Commission File Number: 001-40530
GH Research PLC
(Exact name of registrant as specified in its charter)
Joshua Dawson House
Dawson Street
Dublin 2
D02 RY95
Ireland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
GH Research PLC (the “Company”) will hold one-on-one investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place from January 8-11, 2024, in San Francisco, California.
On January 5, 2024, the Company made available an updated investor presentation on its website. A copy of the investor presentation is attached hereto as
Exhibit 99.1.
The fact that this presentation is being made available and furnished herewith should not be deemed an admission as to the materiality of any information
contained in the materials. The information contained in the presentation is being provided as of January 5, 2024, and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to
reflect subsequent actual results.
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
|
Corporate Presentation for January 2024
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| |
GH Research PLC
|
|
Date: January 5, 2024
|
|
| |
|
| |
By:
|
/s/ Julie Ryan
|
| |
Name:
|
Julie Ryan
|
| |
Title:
|
Vice President, Finance
|
3
Exhibit 99.1
GH Research PLC (NASDAQ: GHRS) January 2024 Corporate Presentation 1
This presentation has been prepared by GH Research PLC (“GH Research”) for
informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or
adviser of GH Research. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. This presentation does not constitute an offer to sell or the solicitation of an offer to buy securities, nor
shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This
presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as
“may”, “anticipate”, “believe”, “could”, “expect”, “should”, “plan”, “intend”, “estimate”, “will”, “potential” and “ongoing”, among others, although not all forward-looking statements contain these identifying words. Any statements contained
herein that do not describe historical facts are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and
performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with GH Research’s research and development
efforts; the inherent uncertainties associated with the conduct, timing and results of nonclinical and clinical studies of GH Research’s product candidates; GH Research’s expectations related to the clinical hold on the GH001 IND, including
plans and expectations for progressing any nonclinical programs and any other work to lift the clinical hold, the timing required to lift such clinical hold and for discussions with the FDA and the outcomes and resolution of such discussions;
GH Research’s ability to obtain, maintain, enforce and defend issued patents; the adequacy of GH Research’s capital resources, the availability of additional funding and GH Research’s cash runway; and other factors, risks and uncertainties
described in GH Research’s filings with the U.S. Securities and Exchange Commission. Except as otherwise noted, these forward-looking statements speak only as of the date of this presentation, and GH Research undertakes no obligation to
update or revise any of such statements to reflect events or circumstances occurring after this presentation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or
quantified and some of which are beyond GH Research’s control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in any such forward-looking statements may not be
achieved or occur and actual results could differ materially from those projected in the forward-looking statements. GH Research cautions you not to place undue reliance on the forward-looking statements contained in this
presentation. Disclaimer Regarding Forward-Looking Statements 2
SeekingUltra-Rapid, Durable Remissionsin Depression 3
Stage of Development PROGRAMS INDICATION PRECLINICAL PHASE 1 PHASE 2a PHASE
2b PHASE 3 CURRENT STATUS GH001Mebufotenin (5-MeO-DMT)for inhalation administration Treatment-Resistant Depression (TRD) Phase 2b RDBPC trial initiated(GH001-TRD-201) Bipolar II Disorder* (BDII) Phase 2a POC trial
initiated(GH001-BD-202) Postpartum Depression (PPD) Phase 2a POC trial initiated(GH001-PPD-203) GH002Mebufotenin (5-MeO-DMT) for i.v. administration Psychiatric or Neurological Disorder Phase 1 HV trial
completed(GH002-HV-105) GH003Mebufotenin (5-MeO-DMT) for nasal administration Psychiatric or Neurological Disorder Pre-clinical development ongoing 4 Complete Ongoing *Bipolar II disorder with a current major depressive
episode 5-MeO-DMT, 5-Methoxy-N,N-Dimethyltryptamine; i.v., intravenous; RDBPC, Randomized, Double-Blind, Placebo-Controlled; POC, Proof-of-Concept; HV, Healthy Volunteer Pipeline
The Problem for Patients with Depression Established Therapies are
Slow-Acting ... Remission Rates in TRD < 15% 5 (STAR*D study, Remission Rate Over Time, Treatment Step 1 = Citalopram) (STAR*D study, Remission Rates Treatment Steps 1 to 4) Average time to remission is ~6 weeks ~33% no remission
despite 4 treatment steps 2 or more prior therapies = TRD Adapted from Trivedi et al., Am J Psychiatry 2006 and Rush et al., Am J Psychiatry 2006 TRD, Treatment-Resistant Depression
First Line MDD Second Line MDD Treatment-Resistant Depression (TRD) Patients
cycle through ineffective therapies for TRD Diagnosed: ~48M Treated (pharmacotherapy ± psychotherapy): ~24M Non-response to first line: ~13M Non-response to two prior lines: ~9M Large and Open Depression Market in the EU and
US 6 Company estimates based on: https://www.nimh.nih.gov/health/statistics/major-depression.shtml; Wittchen et al., The size and burden of mental disorders and other disorders of the brain in Europe 2010, European Neuropsychopharmacology
(2011); Rush et al., Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report, Am J Psychiatry 2006MDD, Major Depressive Disorder
Mebufotenin (5-MeO-DMT) and GH001 7 Mebufotenin
(5-Methoxy-N,N-Dimethyltryptamine, 5-MeO-DMT) Naturally-occurring psychoactive substance from tryptamine class Highly potent agonist on 5-HT1A and 5-HT2A receptors GH001 (Mebufotenin administration via a proprietary pulmonary inhalation
approach) Psychoactive effects with ultra-rapid onset (within seconds) and short duration (5 to 30 min) High propensity to induce peak experiences (PE), which may be a surrogate marker for therapeutic effects Intraday individualized dosing
regimen (IDR) for maximization of ultra-rapid and durable remissions Single visit initial treatment, with no structured psychotherapy Potential for convenient and infrequent retreatment Mebufotenin (5-MeO-DMT) Foundational IP
GH001 – Individualized Dosing Regimen (IDR) for Maximization of Ultra-Rapid and
Durable Remissions 8 GH001 Single Dose: Inter-Person Variability GH001 Individualized Dosing Regimen (IDR):Maximization of Ultra-Rapid and Durable Remissions MADRS score MADRS score MADRS score MADRS score Dose 1 Dose 1 Dose
2 Dose 3 Dose 2 Dose 1 No remission Remission Remission Remission Remission Hypothetical Patient 1 Hypothetical Patient 2 Hypothetical Patient 3 Hypothetical Patient 1 Hypothetical Patient 2 No remission No
remission No remission Dose 1 MADRS score Dose 1 MADRS, Montgomery-Åsberg Depression Rating Scale
Phase 1 Trial in Healthy Volunteers
GH001-HV-101 9 (Completed) Clinicaltrials.gov ID: NCT04640831
Design of Phase 1 Trial in Healthy Volunteers (GH001-HV-101) 10 GH001 2 mg
(n=4) GH001 6 mg (n=6) GH001 12 mg (n=4) GH001 18 mg (n=4) HV (n=18) Part A (Single Dose) Primary Endpoint: Safety until day 7 Peak Experience Scale (PE Scale)1 Part B (IDR) HV (n=4) Primary Endpoint: Safety until day 7 Peak
Experience Scale (PE Scale)1 GH001 IDR6, 12, 18 mg to achieve PE (up to 3 doses, 3h interval) GH001 Administration Day 1 Day 7 Key Assessments Safety PE Scale Cognitive function Safety Safety Cognitive function 1The PE Scale
averages answers scored by the subject by marking a visual analogue scale between 0 and 100 for the following three questions: 1. How intense was the experience; 2. To what extent did you lose control; 3. How profound (i.e., deep and
significant) was the experience? HV, Healthy Volunteer; PE, Peak Experience; IDR, Individualized Dosing Regimen
Part A (Single Dose) and Part B (IDR) – Safety 11 Study Safety Group
review No SAEs All ADRs mild, except two moderate (*) All ADRs resolved spontaneously Inhalation well-tolerated No noteworthy changes in vital parameters, except for temporary, non-clinically relevant increase in heart rate and blood
pressure shortly after administration of GH001 No clinically significant changes in safety laboratory analyses, psychiatric safety assessments or measures of cognitive function ADRs Part A (Single Dose) Part B (IDR) ADRs 2 mg (n=4) 6
mg (n=6) 12 mg (n=4) 18 mg (n=4) IDR1 (n=4) MedDRA Preferred Term Number of Events n n n n Abnormal dreams 1 Anxiety 1 1 Clumsiness 1 Confusional state 1 Euphoric
mood 1 Fatigue 1 1* Feeling hot 1 Flashback 1 Hallucination 1 Head discomfort 1 Headache 2 1 1 Heart rate
increased 1* Hyperacusis 1 Insomnia 1 Mental fatigue 1 Nausea 2 1 1 2 Vision blurred 1 SAE, Serious Adverse Event; ADR, Adverse Drug Reaction, an adverse event with
a relationship code to the investigational product of definite, probable, or possible, or where code is missing; IDR, Individualized Dosing Regimen 16 mg (n=1); 6-12 mg (n=2); 6-12-18 mg (n=1)
Part A – Peak Experience (PE) Dose-Effectsand Inter-Person
Variability 12 Average fordose group PE Scale PE Threshold PE, Peak Experience
Part B – Peak Experience (PE)Effect of Intraday Individualized Dosing Regimen
(IDR) 13 PE Threshold PE, Peak Experience
(Completed) Phase 1/2 Trial inTreatment-Resistant
DepressionGH001-TRD-102 14 Clinicaltrials.gov ID: NCT04698603
15 Design of Phase 1/2 Trial in TRD (GH001-TRD-102) Phase 1 (Single
Dose) Phase 2 (IDR) GH001 12 mg (n=4) GH001 18 mg (n=4) TRD1 (n=8) Primary Endpoint: Safety until day 7 TRD1 (n=8) Primary Endpoint: MADRS remission day 7 (MADRS≤10) GH001 IDR6, 12, 18 mg to achieve PE (up to 3 doses, 3h
interval) TRD, Treatment-Resistant Depression; PE, Peak Experience; MADRS, Montgomery-Åsberg Depression Rating Scale; IDR, Individualized Dosing Regimen; H, Hour; D, Day 1Defined as inadequate response to at least two adequate courses of
pharmacological therapy or one adequate course of pharmacological therapy and at least one adequate course of evidence-based psychotherapy Key Assessments MADRS H2 PE Scale Safety MADRS D1 Cognitive function Safety MADRS
D7 Cognitive function Safety GH001 Administration Day 1 Day 7
Phase 1 (Single Dose) and Phase 2 (IDR) – Safety 16 ADRs Phase 1 (Single
Dose) Phase 2 (IDR) ADRs 12 mg (n=4) 18 mg (n=4) IDR1 (n=8) MedDRA Preferred Term Number of Events n n Abdominal discomfort 1 Anxiety 2 Depressive symptom 1* Dizziness 1 Feeling
abnormal 1 1 Flashback 1 1 2 Headache 2 1 3 Muscle discomfort 1 Muscle spasms 1 Nausea 2* Paresthesia 1 Sensory disturbance 3 SAE, Serious Adverse Event; ADR, Adverse Drug Reaction, an adverse event
with a relationship code to the investigational product of definite, probable, or possible, or where code is missing; IDR, Individualized Dosing Regimen; C-SSRS, Columbia-Suicide Severity Rating Scale; MADRS, Montgomery-Åsberg Depression
Rating Scale 16-12 mg (n=6); 6-12-18 mg (n=2) Study Safety Group review No SAEs All ADRs mild, except three moderate (*) All ADRs resolved spontaneously Inhalation well-tolerated No noteworthy changes in vital parameters, except for
temporary, non-clinically relevant increase in heart rate and blood pressure shortly after administration of GH001 No clinically significant changes in safety laboratory analyses, psychiatric safety assessments or measures of cognitive
function No safety signal relating to suicidal ideation or suicidal behavior, based on C-SSRS and MADRS subscore item “suicidal thoughts”
Phase 1 (Single Dose) – Efficacy (MADRS) 17 2 of 4 (50%) in the 12 mg group
and1 of 4 (25%) in the 18 mg group had a MADRS remission at day 7 2 of 8 patients had a PE and both had a MADRS remission at day 7 MADRS Remission / Response / Improvement Rate Day 7 PE, Peak Experience; MADRS, Montgomery–Åsberg Depression
Rating ScaleMADRS remission = MADRS of ≤10; MADRS response = Reduction of ≥50% from baseline in MADRS; MADRS any improvement = any reduction from baseline in MADRS
Phase 2 (IDR) – Efficacy (MADRS) 18 Primary endpoint met: 7 of 8 patients
(87.5%) had a MADRS remission at day 7, p<0.0001 7 of 8 patients had a PE and 6 of those had a MADRS remission at day 7 MADRS Remission / Response / Improvement Rate Day 7 PE, Peak Experience; MADRS, Montgomery–Åsberg Depression Rating
ScaleMADRS remission = MADRS of ≤10; MADRS response = Reduction of ≥50% from baseline in MADRS; MADRS any improvement = any reduction from baseline in MADRS
Phase 2 (IDR) – Efficacy (MADRS Change from Baseline) 19 Hour 2 Day 1 Day
7 GH001 p=0.0018 p<0.0001 p<0.0001 Primary endpoint met: 7 of 8 patients (87.5%) had a MADRS remission at day 7, p<0.0001 7 of 7 remissions from day 1 and4 of 7 remissions from 2 hours Baseline1 1Baseline mean MADRS=32
MADRS and PE – Observed Improved Outcome in Phase 2 (IDR) vs Phase 1 (Single
Dose) 20 Phase 2 (IDR) Phase 1 (Single Dose) 12 mg Phase 1 (Single Dose) 18 mg MADRS Remission Rate Day 7 87.5% (7 of 8) 50% (2 of 4) 25% (1 of 4) Mean MADRS Change Day 7 -24.4 (-76%) -21.0 (-65%) -12.5 (-40%) Rate of PE 87.5%
(7 of 8) 50% (2 of 4) 0% (0 of 4) Mean PE Score 90.4 (at final dose) 58.2 59.1 PE, Peak Experience; MADRS, Montgomery-Åsberg Depression Rating Scale; IDR, Individualized Dosing Regimen
(Completed) Phase 1 Clinical Pharmacology Trial in Healthy Volunteers
GH001-HV-103 21 Clinicaltrials.gov ID: NCT05163691
Design of Phase 1 Clinical Pharmacology Trial in Healthy Volunteers
(GH001-HV-103) 22 GH001 Administration Day 7 GH001 6 mg (n=8+2 placebo) GH001 12 mg (n=8+2 placebo) GH001 18 mg (n=8+2 placebo) HV (n=30) Single-Dose Part IDR Part HV (n=16) GH001 IDR6, 12, 18 mg to achieve PE (up to 3 doses,
1h interval, n=8) Key Assessments Safety Pharmacokinetics PE Scale Cognitive function Safety Cognitive function Safety Day 30 GH001 IDR6, 12, 18 mg to achieve PE (up to 3 doses, 2h interval, n=8) Primary Endpoint: Pharmacokinetic
profile of mebufotenin (5-MeO-DMT) and bufotenin HV, Healthy Volunteer; PE, Peak Experience;IDR, Individualized Dosing Regimen
Single Dose and IDR – Safety and Further Results Safety Review No SAEs All
ADRs mild All ADRs resolved spontaneously Inhalation well-tolerated No noteworthy changes in vital parameters, except for temporary, non-clinically relevant increase in heart rate and blood pressure shortly after administration of
GH001 No clinically relevant changes in ECG, safety laboratory analyses, peak flow, cognitive function, psychiatric safety assessments, including the C-SSRS Further Results Pharmacokinetic analyses and psychoactive effect assessments (PE
Scale) support that an interval down to 1 hour between individual doses of the IDR is feasible for future clinical trials 23 ADRs Single-dose IDR 6 mg (n=8) 12 mg (n=8) 18 mg (n=8) Placebo (n=6) 1h interval (n=8)1 2h interval
(n=8)2 MedDRA Preferred Term Number of Events n n n n n Abnormal dreams 1 Chest discomfort 1 Crying 2 2 Dizziness 1 Dry
mouth 1 Dyskinesia 1 Fatigue 1 2 1 Headache 3 1 1 1 Hypoesthesia oral 1 Paresthesia oral 1 Retching 1 Somnolence 1 Tachycardia 2 Tension 1 Tremor 1 SAE,
Serious Adverse Event; Adverse Drug Reaction, or ADR, an adverse event with a relationship code to the investigational product of definite, probable, or possible, or where code is missing; IDR, Individualized Dosing Regimen; C-SSRS,
Columbia-Suicide Severity Rating Scale; PE, Peak Experience 16 mg (n=1), 6-12 mg (n=3); 6-12-18 mg (n=4)26-12 mg (n=3); 6-12-18 mg (n=5)
(Initiated) Phase 2b Trial inTreatment-Resistant
DepressionGH001-TRD-201 24 EudraCT Number: 2022-000574-26
Design of Phase 2b Trial in TRD (GH001-TRD-201) 25 GH001 IDR Placebo IDR
n=80 Randomization 1:1 Up to 5 GH001 IDRs may be administered during the OLE pro re nata (PRN), based on specific re-treatment criteria D0 MADRS Primary Endpoint ΔMADRS (per FDA guidance for rapid-acting
antidepressants*) D1 D7 B H2 Scheduled Visit Double-Blind Phase Open-label Extension Phase (OLE) D14 M2 M3 M4 M5 M6 M1 During the OLE, additional clinic visits can be scheduled if required for medical reasons D0 D1 D7 B
H2 PRN The bold solid lines indicate the fixed duration of 7 days (± 1 day) after an IDR with visits on D0, D1 and D7. The bold dotted line indicates the variable duration until a potential GH001 IDR in the OLE. The GH001 IDR consists of up
to 3 increasing doses (6, 12, 18 mg) and the Placebo IDR consists of up to three placebo doses, to achieve a peak experience, given at a 1H interval. As in previously completed trials, the GH001-TRD-201 trial will be conducted under the
supervision of a healthcare provider, but without any planned psychotherapeutic interventions before, during, or after dosing. IDR, Individualized Dosing Regimen; PRN, pro re nata (as needed); B, Baseline; H, Hour; D, Day; M, Month. *FDA
draft guidance for industry “Major Depressive Disorder: Developing Drugs for Treatment”
Three-Layer Protection Strategy 26 LAYER 1: REGULATORY EXCLUSIVITY FDA: 5
years (+2.5 years paragraph IV stay) EMA: 10 years (+1 year for new indication) LAYER 2: PATENTS Patent families filed relating to mebufotenin (5-MeO-DMT), including: Novel uses in various disorders (including inhaled, nasal, buccal,
sublingual, i.v., i.m., s.c. routes) Novel aerosol compositions of matter Novel manufacturing methods and novel salt forms Novel device-related aspects LAYER 3: TECHNICALComplex bioequivalence for systemically-acting
inhalation/intranasal products with high intra- and inter-subject variability
Board of Directors & Executive Management 27 Florian Schönharting Michael
Forer MSc
Chairman of the Board, Co-founder BA, LLB
Vice-Chairman of the Board Dermot Hanley Duncan Moore BSc, MBA
Board Member MPhil, PhD
Board Member Theis Terwey PD Dr. med. CEO, Co-founder Julie Ryan ACA, MAcc, BComm
VP, Finance Magnus Halle BSc
Managing Director, Ireland, Co-founder Aaron Cameron MSc, MBA
Chief Operating Officer Velichka (Villy) Valcheva MD, MSc VP, Clinical Research and Medical Affairs
Scientific Advisors 28 Michael Thase M.D.
Professor of Psychiatry, Perelman School of Medicine
University of Pennsylvania Madhukar Trivedi M.D.
Professor of Psychiatry,
UT Southwestern Medical Center Mark Zimmerman M.D.
Professor of Psychiatry and Human Behavior,
Brown University Eduard Vieta Prof. Dr. Head, Psychiatry Unit,
Hospital Clínic de Barcelona Michael Bauer Prof. Dr. rer. nat. Dr. med.
Chair, Department of Psychiatry and Psychotherapy,
Technische Universität Dresden Malek Bajbouj Prof. Dr. med.
Head, Center for Affective Neuroscience,
Charité, Berlin Johannes Ramaekers Prof. Dr.
Professor, Faculty of Psychology
and Neuroscience of Maastricht University
Anticipated Milestones and Financial Overview GH001 Complete double-blind
phase of European multi-center, randomized, double-blind, placebo-controlled Phase 2b trial in TRD in Q3 2024, and provide top-line data in Q3 or Q4 2024 Provide update on U.S. IND clinical hold and planned Phase 1 clinical pharmacology
trial with proprietary aerosol delivery device after taking into account the conclusions of expected meeting with FDA in Q1 2024 Provide update on timeline for completion of Phase 2a trials in PPD and in BDII in Q1 2024 GH002 Provide
top-line data from completed Phase 1 clinical pharmacology trial in healthy volunteers in Q1 2024 GH003 Complete preclinical development Financial Overview Cash, cash equivalents, other financial assets and marketable securities were
$228.7 million as of September 30, 2023 We believe existing cash, cash equivalents, other financial assets and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements into 2026 29
SeekingUltra-Rapid, Durable Remissionsin Depression 30
